Search
Aminoflavone
go.drugbank.com/drugs/DB19077InvestigationalAminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesArketamine
go.drugbank.com/drugs/DB19150InvestigationalArketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesSubstance P
go.drugbank.com/drugs/DB19198InvestigationalSubstance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).
Categories: Substance P, antagonists & inhibitorsSynonyms: Substance P, Neurokinin pCamizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigationalCamizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally … [L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing
Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor DegradersCarboxyamidotriazole
go.drugbank.com/drugs/DB11960InvestigationalCarboxyamidotriazole has been used in trials studying the treatment of Lymphoma, Lung Cancer, Breast Cancer, Kidney Cancer, and Ovarian Cancer, among others.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGDC-0623
go.drugbank.com/drugs/DB11982InvestigationalGDC-0623 has been used in trials studying the treatment of Solid Cancers.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesBenznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDiacerein
go.drugbank.com/drugs/DB11994ApprovedInvestigationalWithdrawnDiacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is und...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsNaftopidil
go.drugbank.com/drugs/DB12092InvestigationalNaftopidil has been investigated for the treatment of Disorder of Urinary Stent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesVinpocetine
go.drugbank.com/drugs/DB12131InvestigationalVinpocetine has been investigated for the treatment of Epilepsy.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates